These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 22819314)
21. Rapamycin, mycophenolate mofetil, methylprednisolone, and cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-based conditioning regimen to induce partial tolerance to hind limb allografts without cytoreductive conditioning. Pan H; Wang L; Zhang X; Zhang G; Mai H; Han Y; Guo S Transplant Proc; 2008 Jun; 40(5):1714-21. PubMed ID: 18589179 [TBL] [Abstract][Full Text] [Related]
22. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation. Li JM; Gorechlad J; Larsen CP; Waller EK Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205 [TBL] [Abstract][Full Text] [Related]
23. Donor-specific tolerance in fully major histocompatibility major histocompatibility complex-mismatched limb allograft transplants under an anti-alphabeta T-cell receptor monoclonal antibody and cyclosporine A protocol. Siemionow MZ; Izycki DM; Zielinski M Transplantation; 2003 Dec; 76(12):1662-8. PubMed ID: 14688512 [TBL] [Abstract][Full Text] [Related]
25. Vascularized bone grafts within composite tissue allotransplants can autocreate tolerance through mixed chimerism with partial myeloablative conditioning: an experimental study in rats. Huang WC; Lin JY; Wallace CG; Chuang WY; Wei FC; Liao SK Plast Reconstr Surg; 2010 Apr; 125(4):1095-1103. PubMed ID: 20072086 [TBL] [Abstract][Full Text] [Related]
26. Role of thymus in operational tolerance induction in limb allograft transplant model. Siemionow M; Izycki D; Ozer K; Ozmen S; Klimczak A Transplantation; 2006 Jun; 81(11):1568-76. PubMed ID: 16770246 [TBL] [Abstract][Full Text] [Related]
27. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation. Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949 [TBL] [Abstract][Full Text] [Related]
28. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Wekerle T; Kurtz J; Ito H; Ronquillo JV; Dong V; Zhao G; Shaffer J; Sayegh MH; Sykes M Nat Med; 2000 Apr; 6(4):464-9. PubMed ID: 10742157 [TBL] [Abstract][Full Text] [Related]
29. Trafficking of donor-derived bone marrow correlates with chimerism and extension of composite allograft survival across MHC barrier. Ozmen S; Ulusal BG; Ulusal AE; Izycki D; Yoder B; Siemionow M Transplant Proc; 2006 Jun; 38(5):1625-33. PubMed ID: 16797371 [TBL] [Abstract][Full Text] [Related]
30. Stable mixed hematopoietic chimerism permits tolerance of vascularized composite allografts across a full major histocompatibility mismatch in swine. Mathes DW; Solari MG; Gazelle GS; Butler PE; Wu A; Nazzal A; Nielsen GP; Huang CA; Sachs DH; Lee WP; Randolph MA Transpl Int; 2014 Oct; 27(10):1086-96. PubMed ID: 24963743 [TBL] [Abstract][Full Text] [Related]
31. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. Colson YL; Li H; Boggs SS; Patrene KD; Johnson PC; Ildstad ST J Immunol; 1996 Oct; 157(7):2820-9. PubMed ID: 8816385 [TBL] [Abstract][Full Text] [Related]
32. Long-term survival of composite hemiface/mandible/tongue allografts correlates with multilineage chimerism development in the lymphoid and myeloid compartments of recipients. Kulahci Y; Klimczak A; Madajka M; Altuntas S; Siemionow M Transplantation; 2010 Oct; 90(8):843-52. PubMed ID: 20697324 [TBL] [Abstract][Full Text] [Related]
33. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy. Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813 [TBL] [Abstract][Full Text] [Related]
34. Ability of donor splenocytes with costimulation blockade to induce mixed hematopoietic chimerism and transplantation tolerance. Shirasugi N; Emmanouilidis N; Pearson TC; Larsen CP Transplant Proc; 2004 Oct; 36(8):2423-4. PubMed ID: 15561267 [TBL] [Abstract][Full Text] [Related]
35. A clinically feasible approach to induce delayed tolerance in recipients of prior kidney or vascularized composite allotransplants. Chen B; Xu H; Corbin DR; Ildstad ST Transplantation; 2012 Oct; 94(7):671-8. PubMed ID: 22948444 [TBL] [Abstract][Full Text] [Related]
36. Application of chimerism-based drug-induced tolerance to rat into mouse xenotransplantation. Tomita Y; Shimizu I; Iwai T; Zhang QW; Okano S; Kajiwara T; Onzuka T; Tominaga R Scand J Immunol; 2006 Oct; 64(4):392-7. PubMed ID: 16970680 [TBL] [Abstract][Full Text] [Related]
37. Vascularized bone marrow transplantation (VBMT): induction of stable mixed T-cell chimerism and transplantation tolerance in unmodified recipients. Yazdi B; Patel MP; Ramsamooj R; Llull R; Achauer BM; Black KS; Hewitt CW Transplant Proc; 1991 Feb; 23(1 Pt 1):739-40. PubMed ID: 1990672 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic efficacy of polyclonal tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model. Pilat N; Klaus C; Gattringer M; Jaeckel E; Wrba F; Golshayan D; Baranyi U; Wekerle T Transplantation; 2011 Aug; 92(3):280-8. PubMed ID: 21697774 [TBL] [Abstract][Full Text] [Related]
39. Development of donor-specific chimerism and tolerance in composite tissue allografts under alphabeta-T-cell receptor monoclonal antibody and cyclosporine a treatment protocols. Ozer K; Izycki D; Zielinski M; Siemionow M Microsurgery; 2004; 24(3):248-54. PubMed ID: 15160385 [TBL] [Abstract][Full Text] [Related]